All News

ANA neg, but ENA pos should we care about that result? PPV 5.5% here (similar to 6% prev @EricFMorand: https://t.co/Hyaued3rw2) and how many really needed the serology? Anxiety? Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️ #ACR24 ABST1930 @RheumNow https://t.co/rE7RmgOGey

VERY exciting SLE update from Fava et al. Machine learning used to generate urinary protein panel predictive of intra-renal inflammation BETTER than serum biomarkers C3, C4, dsDNA Also monitoring tool for renal response. Outstanding. @RheumNow #ACRbest #ACR24 https://t.co/YXgKrSU4UQ

What a result!!! Crowed split 49% against and 51% for MCTD as a unique disease entity Given pre-debate poll of >70% for MCTD, looks like an overall win for the “NOT” group Fantastic session from all the presenters @RheumNow #ACR24 https://t.co/GgTVQ1VNWP

https://x.com/Dr_Brian_MD/status/1858266822073581805/photo/1

The anti-MCTD group strikes back Of cohort of over 1,000 RNP+ pt, only 17 clinically diagnosed with MCTD Majority of patients, despite potential overlap, treated for other primary rheum dz @RheumNow #ACR24 https://t.co/vkQ6UPs34y

https://x.com/Dr_Brian_MD/status/1858261782160351458/photo/1

Interesting comparative effectivness study, TOFA vs calcineurin inhibitors in MDA5-dermato Expansion of prior publication @NEJM that used historical controls: https://t.co/AzA8ybCqYH Encouraging data for JAKs in this disease; need proper trials #ACR24 @RheumNow Abstr#1736 https://t.co/BHVMZLu6Ip

On now: The Great Debate - is MCTD a distinct clinical entity? @DrLisaCS reviews the history of MCTD classification criteria and its evolution Kasukawa criteria may be most sensitive in one cohort @RheumNow #ACR24 https://t.co/rDHafZVL1I

https://x.com/Dr_Brian_MD/status/1858249504501194915/photo/1

Abstract 1686: Urinary proteomics reveals potential markers (MMP-13, M-CSF receptor, CD163, ALCAM, FOLR2) and pathways (neutrophil degranulation, ECM, tissue remodeling) involved in lupus nephritis Class II. @RheumNow #ACR24 https://t.co/kufd2zl9yc

https://x.com/AkhilSoodMD/status/1858211500739199121/photo/1

Is there a less invasive approach to evaluate lupus nephritis? Abstract 1683 highlights the potential role of 68Ga-FAPI PET imaging in evaluating for lupus nephritis. FAPI uptake ↑ in pts with lupus nephritis vs HC. Correlated with IFN -α and IFN-γ pathways. @RheumNow #ACR24

Will my patient with lupus nephritis respond well to induction therapy? Abstract 1685: Aundhia et al demonstrate the promising utility of RAIL to predict complete renal response in patients with lupus nephritis (Class III or IV +/- V) @RheumNow #ACR24 https://t.co/JBldrrwUhN

https://x.com/AkhilSoodMD/status/1858213010609000758/photo/1

Belimumab, anifrolumab and voclosporin exhibited an increase in claims from 2017-2022 for #SLE Belimumab ~ 600% increase!! @RheumNow #ACR24 abst#1259 https://t.co/norl1xk2KF

https://x.com/bella_mehta/status/1858205209165541866/photo/1

#SLE treatments #ACR24: Compared efficacy & safety of belimumab vs. telitacicept (targets B-lymphocyte stimulator (BLyS) and proliferation-inducing ligand(APRIL)) Both improved disease activity with no difference in efficacy Belimumab had lower infection rates @RheumNow abst1544

More data from PAISLEY, deucravacitinib in SLE Small but significant benefit w/respect to joints, a little disappointing tbh Would like to see this for all manifestations ie pericarditis, pleuritis, etc Anyone have an infographic or useful chart? #ACR20 @RheumNow Abstr#1552 https://t.co/tXUoUtssxo

Low uptake of SGLT2i in Lupus nephritis SGLT2i users had similar adverse event rates as ACEi/ARB users SGLT2i users experienced more weight loss #ACR24 @rheumnow abst#1534 https://t.co/tB5o7tyhu5

https://x.com/bella_mehta/status/1858207474039292036/photo/1

Study on SLE and NMO overlap: Higher risk of acute cystitis & severe sepsis in hospitalized patients SLE/NMO overlap patients 3x more likely to develop acute cystitis 2x more likely to develop severe sepsis #ACR24 @RheumNow abst#1529

Study on SLE treatments: Compared adverse events of anifrolumab vs. belimumab Similar risks for mortality, sepsis, herpes zoster, dialysis, MACE, PE/VTE, COVID-19, URI, pneumonia, and mental illness #ACR24 @RheumNow abst#1527

Study on severe lymphopenia in SLE: - Assessed incidence, risk factors, and outcomes - 11.52% of SLE patients experienced severe lymphopenia - Higher infection rates during severe lymphopenia period = No opportunistic infections observed #ACR24 abst#1519 @rheumnow @HSSProfEd

Study on pregnancy outcomes in SLE with thrombocytopenia: Higher disease activity, pregnancy loss, and stillbirth rates Identified risk factors: Anti-β2GP-I positivity and higher SLEDAI score #ACR24 abst#1487 @RheumNow

Study on cardiovascular deaths in SLE: - Analyzed 1999-2020 data - Overall decline in mortality rates, but recent increase since 2014 - Higher rates in women and African Americans - Geographic disparities noted #ACR24 abst#0998 @rheumnow https://t.co/dpjsl0gI0x

How do we prevent SLE flares requiring steroids? Petri: Background medication! HCQ adherence is key -check WB levels to measure EULAR recs early addition of immunosuppress/biols “Taper quickly, withdraw slowly” Come down quick, then slowly off @RheumNow #ACR24 @jhrheumatology

Petri recommends IM triamcinolone as safer than prednisone dosing per FLOAT trial, decreased risk of fx @RheumNow #ACR24 @jhrheumatology https://t.co/vhMRdSkBAA https://t.co/novlGcss6x

Topics

All News

Do you get our email newsletter?